Amgen’s MariTide shows 20% weight loss in Phase II study

24 June 2025

Obesity late-comer Amgen (Nasdaq: AMGN) announced full results from Part 1 of the Phase II study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently.

In addition to these data, complete results from the primary analysis of the Phase I pharmacokinetics low dose initiation (PK-LDI) study evaluating lower starting doses of MariTide were presented as part of an expert-led Symposium at the American Diabetes Association (ADA) 85th Scientific Sessions and simultaneously published in The New England Journal of Medicine.

If approved, MariTide would be a monthly shot to reduce weight, rivaling weekly injections from Eli Lilly (NYSE: LLY) and Novo Nordisk (NOV: N), and seeking a stake in a competitive obesity market – forecast to reach a value of as much as $173.5 billion in the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK and Japan) by 2031.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK